An announcement from Staar Surgical ( (STAA) ) is now available.
On February 26, 2025, STAAR Surgical Company announced a leadership transition with Stephen C. Farrell appointed as the new President and CEO, succeeding Thomas G. Frinzi. The company also elected Elizabeth Yeu, M.D., as the new Board Chair. This change is expected to leverage Mr. Farrell’s extensive experience in the healthcare industry to navigate global macroeconomic challenges and drive the next phase of STAAR’s growth. The transition aims to enhance STAAR’s market position and capitalize on the growing demand for refractive surgery solutions, with Mr. Frinzi remaining in an advisory role to ensure a smooth transition.
More about Staar Surgical
STAAR Surgical Company is a global leader in the ophthalmic industry, specializing in phakic intraocular lenses (IOLs) with its EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction.
YTD Price Performance: -31.16%
Average Trading Volume: 863,652
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $818.3M
For detailed information about STAA stock, go to TipRanks’ Stock Analysis page.